2nd Quarter - Report

MAGILL ASSOCIATES, LLC for THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2027 appropriations for the development of a synthetic vaccine

LobbyistCovered position, as disclosed
JOHN PIERSON MAGILL COS to Rep. Wally Herger

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

FY 2027 appropriations for the development of a synthetic vaccine

LobbyistCovered position, as disclosed
JOHN PIERSON MAGILL COS to Rep Wally Herger

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.